Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS

NCT03454451 is registered in ClinicalTrials.gov with Corvus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03454451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03454451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Lead sponsor
Corvus Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 25, 2018
Completion date
February 19, 2023
Enrollment
117 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cervical cancer, colorectal cancer, endometrial cancer, metastatic castration resistant prostate cancer, non-hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, renal cell cancer, sarcoma, squamous cell carcinoma of the head and neck, triple negative breast cancer